{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/conjunctivitis-allergic/prescribing-information/topical-ocular-antihistamines-mast-cell-stabilizers/","result":{"pageContext":{"chapter":{"id":"f9e89c16-d4a7-5241-86f6-1f78eacc68fa","slug":"topical-ocular-antihistamines-mast-cell-stabilizers","fullItemName":"Topical ocular antihistamines and mast cell stabilizers","depth":2,"htmlHeader":"<!-- begin field e9aabc5e-96d6-4408-b00f-b79089efbcdc --><h2>Topical ocular antihistamines and mast cell stabilizers</h2><!-- end field e9aabc5e-96d6-4408-b00f-b79089efbcdc -->","summary":"","htmlStringContent":"<!-- begin item 7d89de70-cd0f-47fc-ba2b-38c45a4013d7 --><!-- end item 7d89de70-cd0f-47fc-ba2b-38c45a4013d7 -->","topic":{"id":"b4698c45-6b7c-5244-836f-430591327957","topicId":"27f540e5-bb8e-4cee-a0aa-be515efa4fc2","topicName":"Conjunctivitis - allergic","slug":"conjunctivitis-allergic","lastRevised":"Last revised in October 2020","chapters":[{"id":"bc756208-c2a7-5b33-a4cb-67c41a75ecb0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6470bf56-596c-5d66-b2b2-ba79590bb255","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"17755f2a-0980-50f9-b62e-a34968c9682e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b1dc6613-43b4-55fe-9216-a83aab0ef918","slug":"changes","fullItemName":"Changes"},{"id":"ba5e8d6b-90f7-5b69-b09a-2bb0c2692918","slug":"update","fullItemName":"Update"}]},{"id":"fee1ca82-9d2a-50a4-9230-1a93482b8b4f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"3d036930-da50-5ea2-82e1-1d0fb936a8b4","slug":"goals","fullItemName":"Goals"},{"id":"9ba6a0ce-0eae-5442-85f0-81f7ff71345b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"48935dfe-bca1-53fa-8d50-fa978331bd56","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"35b962f0-ec6b-53c9-b6f2-a5783ae10716","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"8e9984f4-8c0d-5231-9eec-91a9fb49ecc4","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8fa3b231-6e2b-5fa2-aa0c-eb5359ff8160","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ebf46a5d-2a79-5df8-82dd-d23fcb0559f1","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"67185462-9d0a-5b7d-b8af-80b8958f2420","slug":"definition","fullItemName":"Definition"},{"id":"1c320f1a-b91f-5d5b-a47b-dc0094518883","slug":"prevalence","fullItemName":"Prevalence"},{"id":"b21baf96-f39b-5eeb-934b-c193a434933d","slug":"causes","fullItemName":"Causes"},{"id":"923b6415-5fe1-550a-baf5-89285f8ddf77","slug":"complications","fullItemName":"Complications"},{"id":"a679bff6-4749-539e-bdb0-a762a9f91728","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a7d99d63-f47f-54bf-a60f-8ae6f2a42fb9","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"089d5cf7-0f6b-521b-88c1-d4f25eef7101","slug":"assessment","fullItemName":"Assessment"},{"id":"7bb8bdb4-0279-5783-ba21-e44e8bcd0832","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"9a95dbd6-aaa4-5d6a-aa5b-9635d279f9a0","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"51e7c1d5-cd3d-5dea-a8ec-5a38deb58245","fullItemName":"Management","slug":"management","subChapters":[{"id":"e4ced49a-4b06-5559-9efb-c708812a8065","slug":"referral","fullItemName":"Scenario: Referral"},{"id":"77a507ec-4dff-5204-b375-121264b0adf8","slug":"management-in-primary-care","fullItemName":"Scenario: Management in primary care"}]},{"id":"452bc42e-1fe8-56e6-8511-57362d05fe3f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"f9e89c16-d4a7-5241-86f6-1f78eacc68fa","slug":"topical-ocular-antihistamines-mast-cell-stabilizers","fullItemName":"Topical ocular antihistamines and mast cell stabilizers"},{"id":"f9a1678c-7117-5852-af35-628b676780c8","slug":"mast-cell-stabilizers","fullItemName":"Mast cell stabilizers"}]},{"id":"a32b7db8-1764-58b8-adbb-ab8ce0f44e46","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"bd1a2d20-e91f-51f1-a2a2-486ebf015f65","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bc4e76de-c203-5f3e-ad9a-b84d6bc9d81e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"565b3a01-b21e-5837-b9f1-49fda55982ad","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b08973ef-af46-5e6f-b85c-d0bd9ca40bab","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"3003e52e-8597-505e-a3ce-e46fde4c0c20","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"b7947929-e2f9-50c7-b5cd-3e34b802bae1","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3819cbbb-ca8c-58b7-b608-0a9567c5d5b5","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"452bc42e-1fe8-56e6-8511-57362d05fe3f","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"e8de051f-c8d2-548e-aca3-4cc9e2bd31ab","slug":"topical-ocular-antihistamines-mast-cell-stabilizers","fullItemName":"Topical ocular antihistamines and mast cell stabilizers","depth":3,"htmlHeader":"<!-- begin field 1eed3f9a-d840-41e8-8422-de534b6ec5b4 --><h3>Which topical ocular antihistamine or dual action topical antihistamine and mast cell stabilizer can be prescribed?</h3><!-- end field 1eed3f9a-d840-41e8-8422-de534b6ec5b4 -->","summary":"","htmlStringContent":"<!-- begin item fd1d205e-5496-4141-be6b-ea5e6c7a8444 --><!-- begin field e24c8501-2364-4384-9fc5-aeb73d3298e2 --><ul><li>Eye drops containing antihistamines that can be used for allergic conjunctivitis include:<ul><li>Emedastine — licenced for use in seasonal allergic conjunctivitis in adults and children over 3 years, apply twice daily. </li></ul></li><li>Preparations that have dual antihistamine and mast cell stabilizing properties include:<ul><li>Azelastine — licenced for use in seasonal allergic conjunctivitis in adults and children over 4 years, apply twice daily, increased if necessary to 4 times daily; licenced for use in perennial conjunctivitis in adults and children over 12 years, apply twice daily, increased if necessary to 4 times daily; maximum duration of treatment 6 weeks.</li><li>Epinastine — licenced for use in seasonal allergic conjunctivitis in adults and children over 12 years, apply twice daily; maximum duration of treatment 8 weeks.</li><li>Ketotifen — licenced for use in seasonal allergic conjunctivitis in adults and children over 3 years, apply twice daily.</li><li>Olopatadine — licenced for use in seasonal allergic conjunctivitis in adults and children over 3 years, apply twice daily; maximum duration of treatment 4 months.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">BNF 73, 2017</a>] </p><!-- end field e24c8501-2364-4384-9fc5-aeb73d3298e2 --><!-- end item fd1d205e-5496-4141-be6b-ea5e6c7a8444 -->","subChapters":[]},{"id":"7327c4c7-7590-55dc-a502-2762bec74d0b","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field ea536359-5c6c-41b5-99c6-34982a480e1b --><h3>Adverse effects</h3><!-- end field ea536359-5c6c-41b5-99c6-34982a480e1b -->","summary":"","htmlStringContent":"<!-- begin item 9de9ca1f-05ad-477b-9f71-bdd518261377 --><!-- begin field fbee2dc3-3e6f-4474-bfc3-b74de9381544 --><ul><li>Topical eye preparations may cause transient blurring of vision — advise the person to wait until this resolves before driving or performing other skilled tasks such as operating machinery.</li><li>Adverse effects include:<ul><li>Azelastine — mild transient irritation and bitter taste [<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">ABPI, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">BNF 73, 2017</a>].</li><li>Emedastine — transient burning or stinging; blurred vision, local oedema, keratitis, irritation, dry eye, lacrimation, corneal infiltrates (discontinue use) and staining; photophobia; headache, and rhinitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">BNF 73, 2017</a>].</li><li>Epinastine — burning. Less commonly taste disturbance, headache, conjunctival hyperaemia, dry eye, eye pruritus, visual disturbance, increased lacrimation, eye pain, nasal irritation, and rhinitis have been reported [<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">BNF 73, 2017</a>].</li><li>Ketotifen — transient burning or stinging, punctate keratitis, punctate corneal epithelial erosion. Less commonly dry eye, subconjunctival haemorrhage, photophobia; headache, drowsiness, skin reactions, and dry mouth have been reported [<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">ABPI, 2015c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">BNF 73, 2017</a>].</li><li>Olopatadine — local irritation. Less commonly keratitis, dry eye, local oedema, photophobia; headache, asthenia, dysgeusia, fatigue, dizziness and dry nose have been reported [<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">ABPI, 2015d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">BNF 73, 2017</a>].</li></ul></li></ul><!-- end field fbee2dc3-3e6f-4474-bfc3-b74de9381544 --><!-- end item 9de9ca1f-05ad-477b-9f71-bdd518261377 -->","subChapters":[]},{"id":"6ae6fcca-3bd4-572d-b1dc-2881abc5506d","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field d3dff2a3-4f0c-48dd-9b15-a7750106caab --><h3>What are the contraindications and cautions?</h3><!-- end field d3dff2a3-4f0c-48dd-9b15-a7750106caab -->","summary":"","htmlStringContent":"<!-- begin item 43eb395d-c168-4529-827e-a7750106c862 --><!-- begin field d772b2b3-030f-4be6-b912-a7750106caab --><ul><li>Use should be avoided:<ul><li>In people who are hypersensitive to the active substance or to any of the excipients [<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">ABPI, 2015a</a>].</li><li>In people at risk for angle-closure glaucoma [<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">Abelson, 2015</a>].</li><li>With soft contact lenses [<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">ABPI, 2015a</a>].</li><li>In breastfeeding and pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/conjunctivitis-allergic/references/\">ABPI, 2015a</a>].</li></ul></li></ul><!-- end field d772b2b3-030f-4be6-b912-a7750106caab --><!-- end item 43eb395d-c168-4529-827e-a7750106c862 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}